Back to Search Start Over

Oral anticoagulants and cognitive impairment in patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis.

Authors :
Lee, Kun-Han
Yeh, Jiunn-Tyng
Wu, Meng-Lun
Yeh, Wan-Yu
Lip, Gregory Y.H.
Chiang, Chern-En
Chen, Chen-Huan
Cheng, Hao-Min
Source :
Thrombosis Research. Jun2024, Vol. 238, p132-140. 9p.
Publication Year :
2024

Abstract

This systematic review assesses the likelihood of developing dementia and cognitive impairment in patients with atrial fibrillation (AF) receiving non-vitamin K antagonist oral anticoagulants (NOACs) as opposed to vitamin K antagonists (VKAs). We performed a systematic review with meta-analysis and trial sequential analysis (TSA), which encompassed both randomized controlled trials (RCTs) and observational studies. The objective was to assess the impact of NOACs and VKAs on the incidence of dementia in individuals diagnosed with AF. Out of 1914 studies that were screened, 31 studies were included in the final analysis, which consisted of nine RCTs or their subsequent post-hoc analyses, in addition to 22 observational studies. The meta-analysis shows that NOACs were associated with a decreased probability of developing dementia of any cause [Rate Ratio (RR): 0.88; 95 % confidence interval (95 % CI): 0.82–0.94], especially in patients below the age of 75 (RR: 0.78; 95 % CI: 0.73–0.84). Consistent patterns were observed across all forms of dementia and cognitive function decline. The overall evidence indicates notable variability in the outcome with a moderate-to-low degree of certainty. The TSA suggests that the total sample size of the included trials (155,647 patients) was significantly smaller than the required information size of 784,692 patients to discern the true effect of NOAC versus VKA in terms of reducing dementia risk. NOACs may reduce the likelihood of developing dementia in patients with AF, particularly in those under the age of 75. This review highlights the urgent necessity for thorough research to determine the efficacy of NOACs in safeguarding cognitive health. • The optimal treatment to lower incidence of dementia for AF patients remained elusive. • NOACs were associated with a decreased probability of developing all-cause dementia. • The negative association between NOACs and risk of dementia is more prominent in patients <75 years old. • Insufficient required information size was noted to determine the true effect of NOACs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00493848
Volume :
238
Database :
Academic Search Index
Journal :
Thrombosis Research
Publication Type :
Academic Journal
Accession number :
177318243
Full Text :
https://doi.org/10.1016/j.thromres.2024.04.032